GvHD Symposium

GvHD national symposium

Innovative And Life-Changing Research Presentations

The Meredith A. Cowden Foundation presented the 2017 National GvHD Health Symposium at the Grand Event Center in Columbus, OH on Friday, October 13th, 2017. This unique one-day conference consisted of two-tracks – one designed for physicians and other healthcare professionals and one for bone-marrow transplant (BMT) survivors, their families, and their caregivers. Both tracks focused on cutting-edge research and new treatments.

Last year, over 200 people attended this unique event providing an opportunity for survivors, their families, and caregivers to interact with some of the world’s leading authorities on the cause, treatment and management of Graft vs. Host Disease, a complication that affects over 60% of bone marrow transplant patients. It is the only program of its kind in the United States focusing on this very specific complication.

The 2017 Symposium
• Provided a scientifically rigorous and clinically applicable program to medical providers
• Provided programs for mid-level medical professionals and social workers who work with patients, survivors and their families
• Presented programs specifically to the interests of BMT survivors, their families, and their caregivers
• And, brought physicians and patients together to discuss issues, challenges, and successes of dealing with acute and chronic GvHD.

For more information, contact Lyn Haselton at lynhaselton@gmail.com

The Foundation would like to thank the Doctors and the other medical personnel
that gave their time and knowledge to make the 2017 National GvHD Symposium
a great success. We would also like to thank the more than 200 Doctors, medical
personnel, patients, caregivers and families that attended.

This was truly a day of learning for everyone who participated. THANK YOU!

A Unique Conference

For Physicians, Health Care Professionals, And Survivors

This unique conference, which focuses on cutting edge research and new treatments, consists of two tracks: one designed for physicians and other health care professionals, and one for bone marrow transplant (BMT) survivors, their families and their caregivers.

2019 Symposium

Registration for the symposium is coming soon. Special hotel room pricing available via the link below.

2019 8th Annual Graft vs. Host Disease Symposium
Friday, April 26th 2019
Cleveland Airport Marriott
4277 West 150th Street
Cleveland OH 44135

Hotel Booking Info:
Cleveland Airport Marriot
(complimentary parking & basic internet)
Last day to book: 4/15/19
Special group rate: $85.00 per night

2019 Symposium Speakers

KEYNOTE: Joseph H. Antin, MD Dana Farber Cancer Insitute

Dr. Antin received his MD from Cornell University in 1978, and postgraduate training in hematology and medical oncology at DFCI and Brigham and Women’s Hospital. He subsequently served as director of the Bone Marrow Transplantation Service at BWH from 1987 to 1997. He now heads the Stem Cell Transplant Program of the Department of Medical Oncology at DFCI and BWH. He is a founding member and past president of the American Society of Blood and Marrow Transplantation and a past Chairman of the Steering Committee of the BMT Clinical Trial Network.

Oluwatosin (Tosin) Goje, MD Cleveland Clinic

Oluwatosin Goje (Jaiyeoba), who leads the Reproductive Infectious Diseases Program at Cleveland Clinic, is an Obstetrician Gynecologist fellowship-trained in Infectious Diseases at the Medical University of South Carolina, Charleston, SC, one of four academic centers that offer this specialty training in North America.

Colleen Lance, MD Cleveland Clinic

Colleen G. Lance, MD is a staff physician in the Sleep Disorders Center in the Neurological Institute, Cleveland Clinic. She serves as Medical Director for the Cleveland Clinic-Hillcrest Hospital sleep laboratory.
Dr. Lance earned her medical degree from Baylor College of Medicine in Houston, Texas. She completed Internal Medicine residency at the University of Texas Health Science Center at Houston, including a year as Chief Medical Resident. After practicing internal medicine in private practice and as a hospitalist, she returned for fellowship in Sleep Medicine at the University of Texas Health Science Center. During her fellowship, she received the Founder’s Award from the Southern Sleep Society for her research in sleep disordered breathing in bariatric patients. She is board certified in Sleep Medicine through the American Board of Internal Medicine and the American Board of Sleep Medicine.
Dr. Lance has practiced sleep medicine since 2001, including experience at the M.D. Anderson Cancer Center and the Memorial Hermann Hospital System in Houston, Texas. She has been an active member of the American Academy of Sleep Medicine and is currently serving on the Payor Policy and Review Committee. Also, she served as the President of the Texas Society of Sleep Professionals for 2 years. Her passions include the treatment of complex sleep disordered breathing, particularly with non-invasive ventilation for which she has lectured both regionally and nationally. She is currently working on research projects in sleep apnea in relation to male fertility, and the use of commercial sleep monitoring devices in the oncology patient population.

Navneet Majhail, MD Cleveland Clinic

Dr Navneet Majhail is the Director of the Blood & Marrow Transplant Program at the Taussig Cancer Institute, Cleveland Clinic and Professor of Medicine at the Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio. He is also the president-elect of the American Society for Blood and Marrow Transplantation. He specializes in the care of adult patients receiving blood and marrow transplantation. His research focuses on transplant outcomes, health services and health policy issues in blood and marrow transplantation and quality of life and late effects in transplant survivors.

Areej R. El-Jawahri, MD Massachusetts General Hospital

Dr. El-Jawahri is an oncologist specializing in the care of patients with hematologic malignancies and those undergoing hematopoietic stem cell transplantation. Clinically, she takes care of patients with acute leukemia, myelodysplastic syndrome, chronic leukemias, lymphomas, and myelomas. Her research interests include investigating patient-reported outcomes, enhancing patient-centered decision-making interventions, and designing supportive care interventions to improve the care of patients with hematologic malignancies with a special emphasis on patients undergoing hematopoietic stem cell transplantation. Her research also explores models of health care delivery to improve patients’ quality of life and clinical outcomes. She is an active member of the MGH Cancer Outcomes Research Program (CORE). She will also leading efforts in building and developing the MGH Bone Marrow Transplantation Survivorship Program. She has led and conducted multiple clinical trials focusing on enhancing the experience and clinical outcomes of patients with hematologic malignancies.

Amanda Budai, MSW, LCSW UPMC Manger of Social Work

Amanda Budai, MSW, LCSW, earned her Bachelor’s degree in social work from Edinboro University and her Master’s degree in social work from University of Pittsburgh. She has been a clinical social worker at UPMC Cancer Center for 10 years working with patients and families with hematology malignancies, stem cell transplant, and most recently, CAR T therapy. In 2018, she was named Leukemia and Lymphoma Society Hematology-Oncology Social Worker of the Year by the Association of Oncology Social Work. In addition, she serves as a Social Work Board Member for Bone Marrow Foundation, and as a Social Work Continuing Education Committee Member for the National Marrow Donor Program.

John F DiPersio, MD, PhD Washington University School of Medicine in St. Louis

My research focuses on fundamental and translational aspects of leukemia and stem cell biology. These studies include identification of genetic abnormalities in human leukemias, understanding processes involving stem cell and leukemia cell trafficking and clinical and translational programs in both leukemia/MDS and stem cell transplantation. My laboratory also utilizes unique mouse models of allogeneic stem cell transplantation to explore novel genetic and epigenetic interventions aimed at mitigating graft vs. host disease (GvHD) while maintaining graft vs. leukemia (GvL). I am also a PI of multiple clinical trials focused on the diagnosis and treatment of patients with hematologic malignancies or those undergoing allogeneic stem cell transplantation. As Deputy Director of the Siteman Cancer Center I oversee all clinical and basic science research in the cancer center and I am active as a mentor of trainees and junior faculty and oversee faculty recruitment and retention in the Division. My personal research has focused on the role of stem cell transplantation and novel targeted interventions to alter the natural history of AML and other hematological malignancies. These studies have utilized bench-to-bedside mechanistic and preclinical modeling studies followed by early phase clinical trials. They have focused on targeting key elements of the hematopoietic niche for optimal stem cell mobilization and chemosensitization, mitigating GvHD in T replete transplants, understanding the genomic alterations in de novo and relapsed AML and developing and testing in the clinic novel therapeutics and immunotherapeutics for the treatment of AML before and after stem cell transplantation.

Steven Z. Pavletic, MD, MS National Cancer Institute / NIH

Dr. Pavletic received his M.D. from the University of Zagreb School of Medicine in Croatia in 1979. In 1992, he completed a clinical fellowship in bone marrow transplantation at the Fred Hutchinson Cancer Research Center and University of Washington Medical School in Seattle, WA. In 1995, he completed his internal medicine residency at the University of Nebraska Medical Center (UNMC) in Omaha, NE, and completed his hematology and oncology fellowship in June 1997. Until October 2002, Dr. Pavletic served as the director of the Allogeneic Stem Cell Transplantation Program at UNMC. In 2002, Dr. Pavletic received an appointment at the National Cancer Institute (NCI) and an adjunct appointment at the National Institute for Arthritis and Musculoskeletal and Skin Diseases at NIH. Currently, he is the head of the Graft-versus-Host and Autoimmunity Unit in the Experimental Transplantation and Immunology Branch. In October 2006, Dr. Pavletic received the NCI Director’s award for his achievements in developing national and international consensus guidelines for clinical trials in chronic GVHD.

Madan Jagasia, MD Vanderbuilt University Medical Center Associate Professor of Medicine Chief, Section of Hematology-Stem Cell Transplant Director, Outpatient Transplant Program

Dr. Jagasia is an integral part of the long-term transplant clinic with a singular focus on delivering efficient and effective care to the transplant patient. His primary research interest is graft-versus-host disease (GVHD), an immune complication of allogeneic stem cell transplantation.

As a clinical investigator, he is actively trying to identify non-HLA genetic factors that predict development of both acute and chronic GVHD. The development of biomarkers that predict for type of organs affected with GVHD along with response to therapy is an important aspect of his research. He is actively involved in clinical trials targeting various manifestations of chronic GVHD, and is the site principal investigator for the national chronic GVHD consortium.

Dr. Jagasia received his MBBS from King Edward Memorial College in Mumbai, India. He received his fellowship training at Vanderbilt University in hematology-oncology. He pursued his Masters of Science in Clinical Investigation at Vanderbilt from 2004-2006.

Dr. Jagasia has authored and co-authored more than 80 research articles in peer reviewed-journals such as Blood, Journal of Clinical Oncology, Bone Marrow Transplantation and Biology of Blood and Marrow Transplantation. He has served as a reviewer for many of these journals. He is a member of the GVHD and Leukemia working committees for the of International Blood and Marrow Transplant Center.

Michael Pulsipher, MD Children Hospital Los Angeles

Dr. Pulsipher joined the Children’s Center for Cancer and Blood Diseases as the Head of the Section of Blood and Marrow Transplantation (BMT) and as BMT Clinical Research Chair in 2015. He is currently group chair of the Pediatric Blood and Marrow Transplant Consortium – an 80-member international clinical trials group—and is recognized as a leading influence in the field of pediatric BMT. He is currently principal or co-principal investigator on six national, multi-center studies and a co-investigator on multiple additional clinical trials. Dr. Pulsipher has authored more than 180 articles in peer-reviewed journals including New England Journal of Medicine, Journal of Clinical Oncology, Journal of Clinical Investigation, Blood, and Nature Genetics. He has also written twelve book chapters and presented widely at national and international conferences.
Clinical Interests
Dr. Pulsipher performs allogeneic and autologous transplantation for a wide variety of cancers, bone marrow disorders, and genetic diseases. He has significant expertise in allogeneic transplantation for acute leukemias, especially ALL, where he has run national research trials and published extensively. Another area Dr. Pulsipher is interested in is reducing toxicity approaches to transplantation of non-malignant disorders, and he is running national research protocols for patients with immunodeficiencies, HLH, and bone marrow failure disorders, specifically severe aplastic anemia. Finally, Dr. Pulsipher has become a national leader in cell therapy research and has organized or chaired national trials testing CAR T-cells and Viral Specific T-cells.

Jennifer Holter-Chakrabarty, MD Stephenson Cancer Center

Jennifer Holter-Chakrabarty, MD is an associate professor of medicine in the section of hematology/oncology. She is also an adjunct associate professor of radiation oncology and holds the Inasmuch Foundation Chair in Cancer Screening, Education, and Outreach.
A lifelong Sooner, Jennifer received her Bachelor of Zoology with distinction from the University of Oklahoma. Dr. Holter attended medical school, residency, and fellowship at the University of Oklahoma. She is one of several active bone marrow transplant physicians at the Stephenson Cancer Center.
In education, she is a member of the Admission Board Committee, and will serve as chair for a three-year term starting in July 2014.
Her research interests include leukemia, transplantation, and imaging of marrow failure syndromes. In these endeavors, she has been funded locally and has collaborated with the National Cancer Institute to move her bench work to the bedside. She is currently the lead investigator at the Stephenson Cancer Center for a “Multi-Institutional Prospective Pilot Study of Lupron to Enhance Lymphocyte Immune Reconstitution following Allogeneic Transplantation in Post-pubertal Children and Adults with Molecular Imaging Evaluation.”
Dr. Holter strongly believes in training the next generation of medical and research professionals, guaranteeing excellence in oncology care for Oklahoma in the future.

Marcel R. M. van den Brink, MD, PhD Memorial Sloan Kettering Cancer Center

Physician-scientist Marcel R. M. van den Brink studies the immunology of bone marrow transplantation. His expertise is in allogeneic (donor-provided) blood stem cell transplantation for adult cancer patients. Allogeneic hematopoietic stem cell transplantation (HSCT) is a therapy for a variety of malignancies, including leukemias, lymphomas and myeloma. Several complications limit its use including relapse of malignancy, graft versus host disease, and prolonged immune depletion caused by the conditioning required for successful transplantation – all of which can lead to increased morbidity and mortality after allo-HSCT. His laboratory uses murine HSCT models to study clinically important problems in HSCT and to test novel therapeutic strategies which can be translated into clinical practice. Van den Brink’s major projects include strategies to enhance post-transplant immune reconstitution, the role of T cells in graft-versus-host-disease and graft-versus-tumor activity.

Support The 2019 Symposium

Become a Sponsor

The following sponsorship opportunities are currently available.
Please contact Lyn Haselton, Event Coordinator, by emailing her at lynhaselton@gmail.com
if you have questions or are interested in other opportunities not listed.

$10,000 –Symposium Host Sponsor

• Logo recognition during the plenary session
• Company logo will appear in symposium syllabus
• Four complimentary meeting registrations

$7,500 – Speaker or Food/Beverage Sponsor

• Logo recognition during the plenary session
• Company logo will appear in symposium syllabus
• Three complimentary meeting registrations

$5,000 – Plenary Session Sponsor

• Logo recognition during the plenary session
• Company name recognition in symposium syllabus
• Two complimentary meeting registrations

$2,500 – Patient Scholarship Sponsor

• Logo recognition during the plenary session
• Company name recognition in symposium syllabus
• One complimentary meeting registration

$2,000 – Symposium Video Sponsor

• Receive logo recognition at beginning and end of the video. The video will be used for patient education and information only and will be available through the Meredith A. Cowden Foundation website and other BMT patient service organizations.
• One complimentary meeting registration

$1,500 – Exhibit Tables

Symposium Speakers Past

GvHD Symposium Speakers - Past

Jeffery J. Auletta, MD
Assistant Professor
Pediatric Hematology Oncology
University Hospitals Case Medical Center
Case Western Reserve University

Kenneth R. Cooke, MD
Ohio Eminent Scholar and Leonard P. Hannah Professor in Stem Cell and Regenerative Medicine
National Center for Regenerative Medicine
Case Western Reserve University
Director, Pediatric BMT Program and The Multidisciplinary Initiative in GVHD
University Hospitals Case Medical Center

Ellen R. Frank, PhD
Bone Marrow Transplant Survivor
Senior Chair, Dana-Farber Patient
Advisory Council

Angie Giallourakis, PhD
Adjunct Faculty, Special Education
Cleveland State University

Stanton L. Gerson, MD
Professor of Hematological Oncology
Director, NCI-designated Case Comprehensive Cancer Center
Director, National Center for Regenerative Medicine (NCRM)
Case Western Reserve University Director, Ireland Cancer Center
University Hospitals Case Medical Center

Mary Guay, PA
Physician Assistant
Hillman Cancer Center

Matt E. Kalaycio, MD, FACP
Professor, Cleveland Clinic Lerner College of Medicine at CWRU
Staff, Hematologic Oncology and Blood Disorders Taussig Cancer Institute, Cleveland Clinic

Mandy C. Leonard, BS, PharmD,BCPS
Assistant Professor, Cleveland Clinic
Lerner College of Medicine at CWRU
Assistant Director, Drug Information Service, Cleveland Clinic

George B. McDonald, MD
Professor of Medicine
University of Washington School of Medicine
Head, Gastroenterology/Hepatology Section
Fred Hutchinson Cancer Research Center

Christy Paddon, LMSW
Medical Social Worker
Blood and Marrow Transplant Program
Roswell Park Cancer Institute

Steven Z. Pavletic, MD, MS
Experimental Transplantation and
Immunology Branch Staff Clinician
National Cancer Institute

Pavan Reddy, MD
Associate Professor
Department of Internal Medicine
University of Michigan

Sue Stewart
Founder and CEO, Blood and Marrow
Transplant Information Network

Marcel R.M. van den Brink, MD, PhD
Professor of Medicine and Immunology
Weill Medical College, Cornell University
Head, Division of Hematologic Oncology
Memorial Sloan Kettering Cancer Center

Daniel J. Weisdorf, MD
Professor, Department of Medicine
Masonic Cancer Center
University of Minnesota
Scientific Director, National Marrow Donor Program

Catherine Bollard, MBChB, MD
Associate Professor of Pediatrics,
Medicine and Immunology
Baylor College of Medicine
Center for Cell and Gene Therapy

Ryan N. Bookout, PharmD, BCOP
Department of Blood and Marrow Transplantation
H. Lee Moffi tt Cancer Center and Research Institute

Anthony G. Brickner, PhD
Assistant Professor of Medicine
Immunology and Clinical and Translational Science
University of Pittsburgh Cancer Institute

Paul Carpenter, MBBS
Associate Professor
Department of Pediatrics
Fred Hutchinson Cancer Research Center

Stanton L. Gerson, MD
Professor of Medicine
Division of Hematology and Oncology
Director, Case Comprehensive Cancer Center
Case Western Reserve University SOM
Director, Seidman Cancer Center
University Hospitals Case Medical Center

Flora Hoodin, PhD
Professor, Department of Psychology
Eastern Michigan University
Adjunct Clinical Associate Professor
Department of Psychiatry
University of Michigan

Hillard M. Lazarus, MD
Professor of Medicine
Division of Hematology and Oncology
Case Western Reserve University SOM
Chair, Cancer IRB
University Hospitals Case Medical Center

Lindsay Maurath, MS
Outpatient Dietitian
Cleveland Clinic

Robert S. Negrin, MD
Professor of Medicine
Medical Director, Clinical Bone Marrow Transplantation Laboratory
Division Chief, Blood and Marrow Transplantation Program
Stanford University

Joseph C. Noreika, MD
Excellence in Eyecare Inc., Medina, OH
Consulting Staff
Summa Wadsworth-Rittman Hospital

Sophie Paczesny, MD, PhD
Assistant Professor, Pediatrics and Communicable Diseases
Blood and Marrow Transplant Program
University of Michigan

Gerard Socie, MD, PhD
Professor and Head, Hematology / Transplantation
Hospital Saint Louis, Paris, France

Robert J. Soiffer, MD
Chief, Division of Hematologic Malignancies
Co-Chief, Stem Cell/Bone Marrow Transplantation Program
Dana-Farber Cancer Institute

Claudio Anasetti, MD
Professor and Chair
Department of Blood & Marrow Transplant
H. Lee Moffi tt Cancer Center & Research Institute

Kenneth R. Cooke, MD Ohio Eminent
Scholar and Leonard C. Hanna Professor in Stem Cell and Regenerative Medicine
Case Western Reserve University
Director, Pediatric Blood and Marrow Transplantation Program
Director, Multidisciplinary Initiative in Graft-vs-Host Disease
University Hospitals Case Medical Center

Corey S. Cutler, MD, MPH, FRCPC
Assistant Professor
Department of Medicine
Harvard Medical School
Dana-Farber Cancer Institute

Tanya Edwards, MD
Cleveland Clinic

Matt Kalaycio, MD, FACP
Professor, Cleveland Clinic Lerner
College of Medicine of Case Western Reserve University
Director, Bone Marrow Transplant Program
Taussig Cancer Institute, Cleveland Clinic

Stanton L. Gerson, MD
Professor of Medicine
Division of Hematology and Oncology
Director, Case Comprehensive Cancer Center
Case Western Reserve University SOM
Director, Seidman Cancer Center
University Hospitals Case Medical Center

Sandra Mitchell, PhD, CRNP
Research Scientist, Outcomes Research
Branch Nurse Practitioner
NCI Chronic Graft-Versus-Host-Disease Clinic and Study Group

William J. Murphy, PhD
Professor and Vice Chair
Department of Dermatology
University of California – Davis

Steven Pavletic, MD, MS
Experimental Transplantation and
Immunology Branch
National Cancer Institute

Effie Petersdorf, MD
Professor, Department of Medicine
University of Washington
Attending Physician
Seattle Cancer Care Alliance

Stefanie Sarantopoulos, MD, PhD
Assistant Professor
Department of Medicine
Division of Hematology/Oncology
University of North Carolina

Warren D. Shlomchik, MD
Associate Professor
Department of Medicine
Smilow Cancer Hospital
Yale School of Medicine

Keren Stronach, MPH
Health Care Navigator
UCSF Comprehensive Cancer Center

Keith M. Sullivan, MD
Department of Medicine
Division of Cellular Therapy
Duke University Medical Center

2016, 2017, 2018

GvHD Symposium Sponsors

Case Comprehensive Cancer Center
The Case Comprehensive Cancer Center (Case CCC) based at Case Western Reserve University (CWRU) is a partnership organization supporting all cancer-related research efforts at CWRU, University Hospitals Case Medical Center, and the Cleveland Clinic. Located in Cleveland, Ohio, the Case CCC serves the cancer research and clinical needs of an urban manufacturing and rural agricultural region containing 3.8 million people in Northern Ohio

University Hospitals Seidman Cancer Center
University Hospitals Seidman Cancer Center, part of the Case Comprehensive Cancer Center, is dedicated to the innovative treatment and promising research in the fight against cancer through ongoing studies aimed at cancer treatment and prevention.

One of only 41 Comprehensive Cancer Centers in the country designated by the National Cancer Institute (NCI), Seidman can offer cutting-edge treatments earlier than most other cancer centers. Our affiliation with Case Western Reserve University provides ongoing studies aimed at cancer treatment and prevention.

Patients receive skilled care through our multidisciplinary team approach. Experts in surgery, medical oncology, radiation therapy, pathology, nursing, social work, and psychology work together to create a personalized treatment plan that meets physical, emotional and spiritual needs.

Recognized by U.S. News and World Report as one of the top hospitals for cancer care in the country, the mission of Seidman Cancer Center is simple: to cure cancer

Cleveland Clinic Taussig Cancer Institute
Taussig Cancer Institute provides world-class care to patients with cancer and is at the forefront of new and emerging clinical, translational and basic cancer research.

Cleveland Clinic is moving toward the forefront of the cancer drug discovery revolution and cancer research. Through cancer research, we have identified new molecules with anti-tumor effects, developed collaborative ties with biotechnology companies, begun training more young scientists and expanded our base of financial support. These bold steps in cancer research will result in discovery and application of new therapies to help us eliminate cancer as a significant cause of mortality.

Other Sponsors

Acknowledgments

Grants Provided by
Incyte Pharmaceuticals
Mallinckrodt Pharmaceuticals

Exhibits Provided by
AbbVie
Amgen
Avadim Technologies, Inc.
Celgene Corportation
Jazz Pharmaceuticals
Pfizer, Inc.
Pharmacyclics LLC and Janssen Biotech, Inc.
Seattle Genetics

Other Support Provided by
Pharmacyclics LLC and Janssen Biotech, Inc.
Acceptance of funding in support of this program does not constitute the endorsement of any product or manufacturer.

Patient Resource Exhibitors
BMTInfoNet
Leukemia & Lymphoma Society
Meredith A. Cowden Foundation
National Marrow Donor Program
nbmtLink

Pin It on Pinterest